21375YP

In the Claims

1 (Currently Amended) A compound represented by Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein

HET is one of the following heterocycles:



R^1 is

(a) H;

(b) C_1-C_6-alkyl, C_2-C_4-alkenyl, C_2-C_4-alkynyl,C_3-C_6-cycloalkyl, or C_1-C_4-alkyl-[C_3-C_6-cycloalkyl], any of which is optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, $S(O)_{0-2}$-(C_1-C_4)alkyl, O-$CONR^aR^b$, NR^aR^b, $N(R^a)CONR^aR^b$, COO-(C_1-C_4)alkyl, COOH, CN, $CONR^aR^b$, $SO_2NR^aR^b$, $N(R^a)SO_2NR^aR^b$, -$C(=NH)NH_2$, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(c) -O-C_1-C_6-alkyl, -O-C_3-C_6-cycloalkyl, -S-C_1-C_6-alkyl or -S-C_3-C_6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-

C_4)alkyl, $S(O)_{0-2}$-(C_1-C_4)alkyl, O-$CONR^aR^b$, NR^aR^b, $N(R^a)CONR^aR^b$, COO-(C_1-C_4)alkyl, COOH, CN, $CONR^aR^b$, $SO_2NR^aR^b$, $N(R^a)SO_2NR^aR^b$, -C(=NH)NH_2, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(d) -C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl, or -O-C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl;

(e) -OH;

(f) -O-aryl, or –O-C_1-C_4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C_{0-4}alkyl-CO-OR^a, viii) -(C_{0-4}alkyl)-NH-CO-OR^a, ix) -(C_{0-4}alkyl)-CO-$N(R^a)(R^b)$, x) -$S(O)_{0-2}R^a$, xi) -$SO_2N(R^a)(R^b)$, xii) -$NR^aSO_2R^a$, xiii) -C_{1-10}alkyl, and xiv) -C_{1-10}alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -$S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-$N(R^a)$-, -$N(R^a)$-C(O)-, -$N(R^a)$-C(O)-$N(R^a)$-, -C(O)-, -CH(OH)-, -CH=CH-, or -C≡C- ;

(g) -$OCON(R^a)(R^b)$, or -$OSO_2N(R^a)(R^b)$;

(h) -SH, or -$SCON(R^a)(R^b)$;

(i) NO_2;

(j) NR^aR^b, -$N(COR^a)R^b$, -$N(SO_2R^a)R^b$, -$N(R^a)SO_2N(R^a)_2$, -$N(OR^a)CONR^aR^b$, -$N(R^a)SO_2R^a$ or -$N(R^a)CON(R^a)_2$;

(k) -$CH(OR^a)R^a$, -$C(OR^b)CF_3$, -$CH(NHR^b)R^a$, -$C(=O)R^a$, $C(=O)CF_3$, -$SOCH_3$, -SO_2CH_3, $COOR^a$, CN, $CONR^aR^b$, -$COCONR^aR^b$, -$SO_2NR^aR^b$, -CH_2O-$SO_2NR^aR^b$, $SO_2N(R^a)OR^a$, -C(=NH)NH_2, -CR^a=N-OR^a, CH=$CHCONR^aR^b$;

(l) -$CONR^a(CH_2)_{0-2}C(R^a)(R^b)(CH_2)_{0-2}CONR^aR^b$;

(m) tetrazolyl, tetrazolinonyl, triazolyl, triazolinonyl, imidazolyl, imidozolonyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrazolonyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, or phenyl, any of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) -C(=O)R^a, v) C_1-C_6-alkyl , vi) -O-R^a, vii) -NR^aR^b , viii) - C_0-C_4-alkyl -CO-O R^a, ix) -(C_0-C_4-alkyl)-NH-CO-OR^a, x) -(C_0-C_4-alkyl)-CO-NR^a R^b, xi) –$S(O)_{0-2}R^a$, xii) -$SO_2NR^aR^b$, xiii) -$NHSO_2R^a$, xiv) –C_1-C_4-perfluoroalkyl, and xv) –O-C_1-C_4-perfluoroalkyl;

(n) -$C(R^a)$=$C(R^b)$-$COOR^a$, or -$C(R^a)$=$C(R^b)$-$CONR^aR^b$;

21375YP

(o)



or

(p) piperidin-1-yl, morpholin-4-yl, pyrrolidin-1-yl, piperazin-1-yl or 4-susbstituted piperazin-1-yl, any of which is optionally substituted with 1-3 substituents selected from i) -CN, ii) -C(=O)(R^a), iii) C_1-C_6-alkyl , iv) -OR^a, v) -NR^aR^b, vi) -C_0-C_4-alkyl-CO-OR^a, vii) -(C_0-C_4-alkyl)-NH-CO-OR^a, viii) -(C_0-C_4-alkyl)-$CON(R^a)(R^b)$, ix) -SR^a, x) -$S(O)_{0-2}R^a$, xi) -$SO_2N(R^a)(R^b)$, xii) -$NR^aSO_2R^a$ xiii) -C_1-C_4-perfluoroalkyl and xiv) -O-C_1-C_4-perfluoroalkyl;

R^a is

(a) H;

(b) C_1-C_4-alkyl, optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, $S(O)_{0-2}$-(C_1-C_4)alkyl, -$OCONH_2$, -OCONH(C_1-C_4alkyl), -OCON(C_1-C_4alkyl)(C_1-C_4alkyl), -OCONHC_1-C_4alkyl-aryl), -OCON(C_1-C_4alkyl)(C_1-C_4alkyl-aryl), NH_2, NH(C_1-C_4alkyl), N(C_1-C_4alkyl)(C_1-C_4alkyl), NH(C_1-C_4alkyl-aryl), N(C_1-C_4alkyl)(C_1-C_4alkyl-aryl), $NHCONH_2$, NHCONH(C_1-C_4alkyl), NHCONH(C_1-C_4alkyl-aryl), -NHCON(C_1-C_4alkyl)(C_1-C_4alkyl), NHCON(C_1-C_4alkyl)(C_1-C_4alkyl-aryl), N(C_1-C_4alkyl)CON(C_1-C_4alkyl)(C_1-C_4alkyl), N(C_1-C_4alkyl)CON(C_1-C_4alkyl)(C_1-C_4alkyl-aryl), COO-(C_1-C_4-alkyl), COOH, CN, $CONH_2$, CONH(C_1-C_4alkyl), CON(C_1-C_4alkyl)(C_1-C_4alkyl), SO_2NH_2, SO_2NH(C_1-C_4alkyl), SO_2NH(C_1-C_4alkyl-aryl), SO_2N(C_1-C_4alkyl)(C_1-C_4alkyl), $NHSO_2NH_2$, -C(=NH)NH_2, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(c) C_0-C_4-alkyl-(C_1-C_4)-perfluoroalkyl; or

(d) C_1-C_4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –C(=O)(C_1-C_4-alkyl), v) -O(C_1-C_4-alkyl), vi) -N(C_1-C_4-alkyl)(C_1-C_4-alkyl), vii) -C_{1-10}alkyl, and viii) -C_{1-10}alkyl,wherein one or more of the alkyl carbons can be replaced by a -O-, -$S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-, -CH(OH)-, -CH=CH-, or -C≡C-;

21375YP

R^b is

(a) H; or

(b) C_1-C_6-alkyl, optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, $S(O)_{0-2}$-(C_1-C_4)alkyl, -$OCONH_2$, -OCONH(C_1-C_4alkyl), NH_2, NH(C_1-C_4alkyl), N(C_1-C_4alkyl)(C_1-C_4alkyl), $NHCONH_2$, NHCONH(C_1-C_4alkyl), -NHCON(C_1-C_4alkyl)(C_1-C_4alkyl), COO-(C_1-C_4-alkyl), COOH, CN, and $CONH_2$;

R^2 is:

(a) H;

(b) -C_1-C_4-alkyl, -C_3-C_6-cycloalkyl or -C_1-C_4-alkyl-(C_3-C_6)-cycloalkyl, optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, $S(O)_{0-2}$-(C_1-C_4)alkyl, O-$CONR^aR^b$, NR^aR^b, $N(R^a)CONR^aR^b$, COO-(C_1-C_4)alkyl, COOH, CN, $CONR^aR^b$, $SO_2NR^aR^b$, $N(R^a)SO_2NR^aR^b$, -C(=NH)NH_2, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl and piperazinyl;

(c) -C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl;

(d) aryl or -(C_1-C_4-alkyl)-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C_{0-4}alkyl-CO-OR^a, viii) -(C_{0-4}alkyl)-NH-CO-OR^a, ix) -(C_{0-4}alkyl)-CO-N(R^a)(R^b), x) -$S(O)_{0-2}R^a$, xi) -$SO_2N(R^a)(R^b)$, xii) -$NR^aSO_2R^a$, xiii) -C_{1-10}alkyl, and xiv) -C_{1-10}alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, - O-, -$S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -CH=CH-, or -C≡C-; or

(e) -C(=O)(R^a), -$CONR^aR^b$, COO-(C_1-C_4)alkyl, - SO_2R^a, -$SO_2N(R^a)(R^b)$;

R^3 is

(a) H;

(b) -C_1-C_4-alkyl, -C_3-C_6-cycloalkyl or -C_1-C_4-alkyl-(C_3-C_6)-cycloalkyl, optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, $S(O)_{0-2}$-(C_1-C_4)alkyl, O-$CONR^aR^b$, NR^aR^b, $N(R^aR^b)CONR^aR^b$, COO-(C_1-C_4)alkyl, COOH, CN, $CONR^aR^b$, $SO_2NR^aR^b$, $N(R^aR^b)SO_2NR^aR^b$, -C(=NH)NH_2, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(c) -C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl;

(d) aryl or -(C_1-C_4-alkyl)-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C_{0-4}alkyl-CO-OR^a, viii) -(C_{0-4}alkyl)-NH-CO-OR^a, ix) -(C_{0-4}alkyl)-CO-N(R^a)(R^b), x) -$S(O)_{0-2}R^a$, xi) -$SO_2N(R^a)(R^b)$, xii) -$NR^aSO_2R^a$, xiii) -C_{1-10}alkyl, and xiv) -C_{1-10}alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, - O-, -$S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -CH=CH-, or -C≡C- ;

(e) -O-C_1-C_4-alkyl, -O-C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl, -O-aryl or -O(C_1-C_4-alkyl)-aryl; or

(f) -C(=O)(R^a), -SO_2R^a, -$SO_2N(R^a)(R^b)$, CN, NR^aR^b, NO_2, F, Cl, Br, I, OH, $OCONR^aR^b$, O(C_1-C_4-alkyl)$CONR^aR^b$,-$OSO_2NR^aR^b$, $COOR^a$, or $CONR^aR^b$;

R^4 and R^5 each independently is:

(a) H;

(b) ~~C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl or C_3-C_6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3, -O-(C_1-C_4)alkyl, CN, -N(R^a)(R^b), -N(R^a)CO-(C_1-C_4)alkyl, $COOR^b$, $CON(R^a)(R^b)$ or phenyl;~~

~~(c) O-C_0-C_6-alkyl, O-aryl, or -O-C_1-C_4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) CN, iii) NO_2, iv) C(=O)(R^a), v) OR^a, vi) NR^aR^b, vii) C_{0-4}alkyl-CO-OR^a, viii) (C_{0-4}alkyl)-NH-CO-OR^a, ix) (C_{0-4}alkyl)-CO-N(R^a)(R^b), x) $S(O)_{0-2}R^a$, xi) $SO_2N(R^a)(R^b)$, xii) $NR^aSO_2R^a$, xiii) C_{1-10}alkyl, and xiv) C_{1-10}alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -$S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;~~

~~(d) C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl, or -O-C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl; or~~

~~(e) CN, NH_2, NO_2, F, Cl, Br, I, OH, $OCON(R^a)(R^b)$, O(C_1-C_4-alkyl)$CONR^aR^b$, $OSO_2N(R^a)(R^b)$, $COOR^b$, $CON(R^a)(R^b)$, or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) CN, iii) NO_2, iv) C(=O)(R^a), v) OR^a, vi) NR^aR^b, vii) C_{0-4}alkyl-CO-OR^a, viii) (C_{0-4}alkyl)-NH-CO-OR^a, ix) (C_{0-4}alkyl)-CO-N(R^a)(R^b), x) $S(O)_{0-2}R^a$, xi) $SO_2N(R^a)(R^b)$, xii) $NR^aSO_2R^a$, xiii) C_{1-10}alkyl, and xiv) C_{1-10}alkyl, wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -$S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-; and~~

R^6, R^7 and R^8 each independently is:

(a) H, provided at least one of R^6, R^7 and R^8 is not hydrogen;

(b) C_1-C_6-alkyl, C_2-C_4-alkenyl, C_3-C_4-alkynyl or C_3-C_6-cycloalkyl, any of which is optionally substituted all substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, $OCON(R^a)(R^b)$, NR^aR^b, $COOR^a$, CN, $CONR^aR^b$, $N(R^a)CONR^aR^b$, $N(R^a)SO_2NR^aR^b$, $SO_2NR^aR^b$, $S(O)_{0-2}(C_1$-C_4-alkyl), $-C(=NH)NH_2$, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, or piperazinyl;

(c) -O- C_1-C_6-alkyl, -O-C_3-C_6-cycloalkyl, -S-C_1-C_6-alkyl, or -S-C_3-C_6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, NH_2, $NH(C_1$-C_4-alkyl), $N(C_1$-C_4-alkyl)$_2$, COOH , CN, $CONH_2$, $CONH(C_1$-C_4-alkyl), $CONH(C_1$-C_4-alkyl)$_2$, SO_2NH_2, $SO_2NH(C_1$-C_4-alkyl), tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, or piperazinyl;

(d) -C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl, or -O-C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl; or

(e) -O-aryl, or -O-C_1-C_4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) $-NO_2$, iv) $-C(=O)(R^a)$, v) $-OR^a$, vi) $-NR^aR^b$, vii) -C_{0-4}alkyl-CO-OR^a, viii) -(C_{0-4}alkyl)-NH-CO-OR^a, ix) -(C_{0-4}alkyl)-CO-$N(R^a)(R^b)$, x) $-S(O)_{0-2}R^a$, xi) $-SO_2N(R^a)(R^b)$, xii) $-NR^aSO_2R^a$, xiii) -C_{1-10}alkyl, and xiv) -C_{1-10}alkyl,wherein one or more of the alkyl carbons can be replaced by a $-NR^a$-, -O-, $-S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-$N(R^a)$-, $-N(R^a)$-C(O)-, $-N(R^a)$-C(O)-$N(R^a)$-, -C(O)-, -CH(OH)-, -CH=CH-, or -C≡C; (f) CN, $N(R^a)(R^b)$, NO_2, F, Cl, Br, I, $-OR^a$, $-SR^a$, $-OCON(R^a)(R^b)$, $-OSO_2N(R^a)(R^b)$, $COOR^b$, $CON(R^a)(R^b)$, $-N(R^a)CON(R^a)(R^b)$, $-N(R^a)SO_2N(R^a)(R^b)$, $-C(OR^b)R^a$, $-C(OR^a)CF_3$, $-C(NHR^a)CF_3$, $-C(=O)R^a$, $C(=O)CF_3$, $-SOCH_3$, $-SO_2CH_3$, $-NHSO_2(C_{1-6}$-alkyl), $-NHSO_2$-aryl, $SO_2N(R^a)(R^b)$, $-CH_2OSO_2N(R^a)(R^b)$, $SO_2N(R^b)$-OR^a, $-C(=NH)NH_2$, $-CR_a=N$-OR_a, CH=CH or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) $-NO_2$, iv) $-C(=O)(R^a)$, v) $-OR^a$, vi) $-NR^aR^b$, vii) -C_{0-4}alkyl-CO-OR^a, viii) -(C_{0-4}alkyl)-NH-CO-OR^a, ix) -(C_{0-4}alkyl)-CO-$N(R^a)(R^b)$, x) $-S(O)_{0-2}R^a$, xi) $-SO_2N(R^a)(R^b)$, xii) $-NR^aSO_2R^a$, xiii) -C_{1-10}alkyl, and xiv) -C_{1-10}alkyl,wherein one or more of the alkyl carbons can be replaced by a $-NR^a$-, -O-, $-S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-$N(R^a)$-, $-N(R^a)$-C(O)-, $-N(R^a)$-C(O)-$N(R^a)$-, -C(O)-, -CH(OH)-, -CH=CH-, or -C≡C; or when R^6 and R^7 are present on adjacent carbon atoms, R^6 and R^7, together with the benzene ring to which

they are attached, may form a bicyclic aromatic ring selected from naphthyl, indolyl, quinolinyl, isoquinolinyl, quinoxalinyl, benzofuryl, benzothienyl, benzoxazolyl, benzothiazolyl, and benzimidazolyl, any aromatic ring of which is optionally substituted with 1-4 independent substituents selected from i) halogen, ii) -CN, iii) $-NO_2$, iv) -CHO, v) -O-C_{1-4}alkyl, vi) -N(C_{0-4}alkyl)(C_{0-4}alkyl), vii) -C_{0-4}alkyl-CO-O(C_{0-4}alkyl), viii) -(C_{0-4}alkyl)-NH-CO-O(C_{0-4}alkyl), ix) -(C_{0-4}alkyl)-CO-N(C_{0-4}alkyl)(C_{0-4}alkyl), x) -S(C_{0-4}alkyl), xi) -S(O)(C_{1-4}alkyl), xii) $-SO_2$(C_{0-4}alkyl), xiii) $-SO_2$N(C_{0-4}alkyl)(C_{0-4}alkyl), xiv) $-NHSO_2$(C_{0-4}alkyl)(C_{0-4}alkyl), xv) -C_{1-10}alkyl and xvi) -C_{1-10}alkyl in which one or more of the carbons can be replaced by a -N(C_{0-6}alkyl)-, -O-, -$S(O)_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-N(C_{0-6}alkyl)-, -N(C_{0-6}alkyl)-C(O)-, -N(C_{0-6}alkyl)-C(O)-N(C_{0-6}alkyl)-, -C(O)-, -CH(OH), -CH=CH-, or -C≡C-.

2(Original). A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

HET is



3(Original). A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

HET is



4. Canceled.

5. Canceled.

21375YP

6. Canceled.

7. Canceled.

8(Original). A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

R^6 is other than H and is attached at the ortho position.

9(Currently Amended). A compound represented by



, or

10(Currently Amended) A compound according ~~to Claim 1~~ which is represented by



R^6	R^2	R^1
Cl	H	H
Cl	H	COOEt
Cl	H	$CONH_2$
Cl	H	CONH-tBu

21375YP

R^6	R^2	R^1
Cl	H	
Cl	H	NH_2
CF_3	H	COOEt
CF_3	H	$CONH_2$
CF_3	H	H
CF_3	H	NH_2
OCF_3	H	CH_3
OCF_3	H	H
OCF_3	H	NH_2
OCF_3	H	$CONMe_2$
OCF_3	Cl	CH_3
OCF_3	H	$NHSO_2CH_3$
OCF_3	H	CH_2OH
O-Ph	H	$CONH_2$
CF_3	H	NHCONH-iPr
OCF_3	H	NHCONH-iPr
OCF_3	H	$NHCOCH_3$
CF_3	H	$NHCOCH_3$
OCF_3	H	CH_2COOEt
OCF_3	H	CH_2CN
OCF_3	H	CH_2CONH_2
CF_3	H	CH_2CONH_2
OCF_3	H	$NHCONMe_2$
OCF_3	H	
OCF_3	H	2-Pyrimidyl
OCF_3	H	2-Pyridyl
OCF_3	H	2-Oxazolyl
OCF_3	H	2-Imidazolyl
OCF_3	H	2-Pyrazolyl
OCF_3	H	2-(1-Methyl)-imidazolyl

21375YP

R^6	R^2	R^1
OCF_3	H	
OCF_3	H	 , or
OCF_3	H	

11(Currently Amended). A compound represented by

 or 

12(Currently Amended). A compound according to Claim 1 represented by



R_6	R_2	R_1
CF_3	H	H
CF_3	H	COOEt
CF_3	H	$CONH_2$
CF_3	H	$CONHCH_3$
CF_3	COOEt	CH_3
CF_3	$CONH_2$	CH_3
OCF_3	H	H
OCF_3	H	$COOCH_3$
OCF_3	H	$CONH_2$

21375YP

R_6	R_2	R_1
OCF_3	H	COOH
OCF_3	H	CH_2OH
OCF_3	H	$CONH(CH_2)_3OH$, or
O-Ph	H	$CONH_2$

13. Canceled.

14. Canceled.

15. Canceled.

16. Canceled.

17(Original). A pharmaceutical composition comprising a therapeutically effective amount of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

18. Canceled.

19. Withdrawn.

20. Withdrawn.

21. Withdrawn.

22 Withdrawn.

23. Withdrawn.

24. Withdrawn.

25. Withdrawn.

21375YP

26. Withdrawn.

27. Withdrawn.

28. Withdrawn.

29. Withdrawn.

30. Withdrawn.

31. Withdrawn.